MX2022012610A - Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib. - Google Patents

Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib.

Info

Publication number
MX2022012610A
MX2022012610A MX2022012610A MX2022012610A MX2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A
Authority
MX
Mexico
Prior art keywords
fedratinib
methods
treating anemia
ligand trap
subject
Prior art date
Application number
MX2022012610A
Other languages
English (en)
Spanish (es)
Inventor
Abderrahmane Laadem
Steve Ritland
Jay T Backstrom
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2022012610A publication Critical patent/MX2022012610A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2022012610A 2020-04-13 2021-04-12 Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib. MX2022012610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009400P 2020-04-13 2020-04-13
PCT/US2021/026816 WO2021211418A1 (en) 2020-04-13 2021-04-12 Methods for treating anemia using an actriib ligand trap and fedratinib

Publications (1)

Publication Number Publication Date
MX2022012610A true MX2022012610A (es) 2022-11-07

Family

ID=78085002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012610A MX2022012610A (es) 2020-04-13 2021-04-12 Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib.

Country Status (10)

Country Link
US (1) US20230181690A1 (cg-RX-API-DMAC7.html)
EP (1) EP4135736A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023523568A (cg-RX-API-DMAC7.html)
KR (1) KR20230003502A (cg-RX-API-DMAC7.html)
CN (1) CN115427056A (cg-RX-API-DMAC7.html)
AU (1) AU2021256419A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020628A2 (cg-RX-API-DMAC7.html)
IL (1) IL297258A (cg-RX-API-DMAC7.html)
MX (1) MX2022012610A (cg-RX-API-DMAC7.html)
WO (1) WO2021211418A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3227675B1 (en) * 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
CA2983440C (en) * 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
TWI814187B (zh) * 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血
LT3490582T (lt) * 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
US11202818B2 (en) * 2016-09-14 2021-12-21 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018231905A1 (en) * 2017-06-14 2018-12-20 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
MX2021001985A (es) * 2018-08-21 2021-04-28 Sierra Oncology Inc Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis.
MA53745A (fr) * 2018-09-25 2021-08-04 Impact Biomedicines Inc Procédés de traitement de troubles myéloprolifératifs

Also Published As

Publication number Publication date
AU2021256419A1 (en) 2022-10-20
IL297258A (en) 2022-12-01
BR112022020628A2 (pt) 2022-11-29
EP4135736A1 (en) 2023-02-22
WO2021211418A1 (en) 2021-10-21
US20230181690A1 (en) 2023-06-15
KR20230003502A (ko) 2023-01-06
CN115427056A (zh) 2022-12-02
JP2023523568A (ja) 2023-06-06
EP4135736A4 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
Shitara et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Cavaletti Chemotherapy‐induced peripheral neurotoxicity (CIPN): what we need and what we know
Xie et al. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer
EA201590210A1 (ru) Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
Cohen‐Wolkowiez et al. Safety and pharmacokinetics of multiple‐dose anidulafungin in infants and neonates
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
Spigel et al. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study
NZ601111A (en) Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
Webb et al. Randomized, double-blind, controlled study of losartan in children with proteinuria
MX2016004411A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1).
ZA202204075B (en) Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
KR20220024540A (ko) 암 환자에서의 항종양 면역의 증진을 위한 환자 선택
Emens et al. Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors
BR112022020628A2 (pt) Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe
Carlo‐Stella et al. A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
Cotreau et al. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor
MX2022006786A (es) Método de tratamiento de cáncer mediante la administración de un agente terapéutico anti-pd-1 o anti-pd-l1 mediante un dispositivo de administración linfática.
Lu et al. Model‐based meta‐analysis for quantifying Paclitaxel dose response in cancer patients
MX2019004222A (es) Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias.
Forero-Torres et al. Abstract CT056: Preliminary safety, efficacy, and pharmacodynamics of a highly selective PI3Kδ inhibitor, INCB050465, in patients with previously treated B-cell malignancies
MX2022008289A (es) Metodos de tratamiento del carcinoma de celulas renales de celulas claras (ccrcc) utilizando receptores señuelo axl.
Esteban et al. Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies
Azadeh et al. Cetuximab plus various chemotherapy regimens for patients with KRAS wild-type metastatic colorectal cancer
Elishmereni et al. IL-21 immunotherapy in solid cancers: Therapeutic insights from a preclinically validated mathematical pharmacokinetic and pharmacodynamics model